JumpStart Fertility
At-home supplement program designed to naturally enhance fertility and reproductive health for individuals trying to conceive.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | AUD4.0m | Late VC | |
| Total Funding | 000k | ||
Related Content
JumpStart Fertility operates at the intersection of biotechnology and reproductive medicine, focusing on a critical challenge in assisted reproduction: age-related decline in fertility. Founded in 2017 by IVF specialists Dr. Lindsay Wu and Professor Hayden Homer, the company is developing solutions to enhance the success rates of in-vitro fertilization (IVF), particularly for women of advanced maternal age. Dr. Wu leads the Laboratory for Ageing Research at UNSW Sydney, while Professor Homer holds the Chen Chair in Reproductive Medicine at the University of Queensland and serves as the Medical Director at Queensland Fertility Group, bringing deep expertise in oocyte biology and reproductive aging.
The company's core strategy is to improve the quality of egg cells (oocytes) and subsequent embryo development during IVF cycles. JumpStart Fertility's main product in development is a patented NAD⁺-boosting compound. This solution is designed to be added to the standard embryo-culture media used in IVF labs. The goal is to improve the rate of blastocyst formation, a critical stage in embryo development, which can increase the chances of a successful live birth. By enhancing the viability of embryos, the company aims to reduce the number of IVF cycles a patient might need, thereby lowering the associated financial and emotional costs. Pre-clinical research has indicated this approach could lift blastocyst-formation rates significantly.
The firm primarily serves the IVF and assisted reproductive technology market. Its business model appears to be centered on the commercialization of its proprietary culture media additive for use in fertility clinics globally. Headquartered in Sydney, Australia, with a presence in Boston, Massachusetts, JumpStart Fertility is a subsidiary of Life Biosciences, a company focused on developing therapies targeting the biological causes of aging. The company has secured funding from investors including an initial seed round of $500K in 2017 and a subsequent $4 million investment led by Proto Axiom in June 2025 to facilitate human trials and seek regulatory approval.
Keywords: reproductive medicine, IVF success rates, fertility solutions, oocyte quality, embryo development, NAD+ precursor, assisted reproduction technology, age-related infertility, blastocyst formation, fertility treatment, culture media additive, biotechnology, reproductive aging, female infertility, Life Biosciences, Proto Axiom, Lindsay Wu, Hayden Homer, assisted conception, fertility research